# Effect of Methylphenidate on Cancer-related Cognitive Impairment

> **NCT02970500** · PHASE2 · TERMINATED · sponsor: **CHU de Quebec-Universite Laval** · enrollment: 20 (actual)

## Conditions studied

- Breast Cancer Female
- Cancer-Related Condition

## Interventions

- **DRUG:** Methylphenidate HCl 10Mg SR
- **DRUG:** Placebo Group

## Key facts

- **NCT ID:** NCT02970500
- **Lead sponsor:** CHU de Quebec-Universite Laval
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-10-09
- **Primary completion:** 2022-12-31
- **Final completion:** 2022-12-31
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** We decided to close recruitment in December 2022 as we were having trouble recruiting participants who met our inclusion criteria and the study funding was coming to an end.
- **Last updated:** 2023-03-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02970500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02970500, "Effect of Methylphenidate on Cancer-related Cognitive Impairment". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT02970500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*